Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (11996)	12/26/2018 3:21:01 PM
From: Ian@SI	Read Replies (1) \| Respond to of 12215

probably ACAD. It's about $20 off its Nuplazid PDP (Parkinson's Disease Psychosis) high since the CNN hit piece, even though the FDA has reconfirmed its approval decision following a safety review. Expanding the label to include ADP appears to be progressing favourably. Not only would this greatly expand the demand, it may even convince some of the non-scientists influenced by incompetent reporters. :-)